Insight into acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities

Infection and Drug Resistance

Volumn 11, Issue , 2018, Pages 1249-1260

  Asif, Muhammad ^a,b   Alvi, Iqbal Ahmad ^a,c   Ur Rehman, Shafiq ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^c HAZARA UNIVERSITY   (Pakistan)

Author keywords

Antibiotic resistance; Colistin; Phage therapy; Tigecycline

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; COLISTIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED INFECTION; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; HUMAN; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PHAGE THERAPY; PREVALENCE; REVIEW; TAXONOMY;

EID: 85057719865     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S166750     Document Type: Review

References (144)

1. Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A. Antimicrobial resistance of Acinetobacter baumannii to imipenem in Iran: a systematic review and meta-analysis. Open Microbiol J. 2016;10:32–42.
2. Qi L, Li H, Zhang C, et al. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol. 2016;7:483.
3. Beijerinck M. Pigmenten als oxydatieproducten gevormd door bacte-rien. Versl Koninklijke Akad Wetensch Amsterdam. 1911;19:1092–1103.
4. Brisou J, Prevot AR. Studies on bacterial taxonomy. X. The revision of species under Acromobacter group. Annales de l’Institut Pasteur. 1954;86(6):722–728.
5. Baumann P. Isolation of Acinetobacter from soil and water. J Bacteriol. 1968;96(1):39–42.
6. Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter. Annales de l’Institut Pasteur/Microbiologie. 1987;138(5):569–578.
7. Nemec A, Radolfova-Krizova L, Maixnerova M, Vrestiakova E, Jezek P, Sedo O. Taxonomy of haemolytic and/or proteolytic strains of the genus Acinetobacter with the proposals of Acinetobacter courvalinii sp. nov.(genomic species 14 sensu Bouvet & Jeanjean), Acinetobacter dispersus sp. nov.(genomic species 17), Acinetobacter modestus sp. nov., Acinetobacter proteolyticus sp. nov. and Acinetobacter vivianii sp. nov. Int J Syst Evol Microbiol. 2016;66(4):1673–1685.
8. Pourabbas B, Firouzi R, Pouladfar G. Characterization of carbapenem-resistant Acinetobacter calcoaceticus-baumannii complex isolates from nosocomial bloodstream infections in southern Iran. J Med Microbiol. 2016;65(3):235–239.
9. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi J Biol Sci. 2018;25(3):586–596.
10. Maravić A, Skočibušić M, Fredotović Ž, et al. Urban riverine environment is a source of multidrug-resistant and ESBL-producing clinically important Acinetobacter spp. Environ Sci Pollut Res Int. 2016;23(4): 3525–3535.
11. Al Atrouni A, Joly-Guillou M-L, Hamze M, Kempf M. Reservoirs of non-baumannii acinetobacter species. Front Microbiol. 2016;7:49.
12. Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19(2):223–238.
13. Shimose LA, Masuda E, Sfeir M, et al. Carbapenem-resistant Acinetobacter baumannii: concomitant contamination of air and environmental surfaces. Infect Control Hosp Epidemiol. 2016;37(7):777–781.
14. Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am J Infect Control. 2016;44(5):e65–e71.
15. Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob. 2016;15(1):1–6.
16. Silva GM, Morais L, Marques L, Senra V. Pneumonia adquirida na comunidade numa criança saudável por Acinetobacter. Revista Por-tuguesa de Pneumologia. 2012;18(2):96–98.
17. Garnacho-Montero J, Amaya-Villar R, Ferrándiz-Millón C, Díaz-Martín A, López-Sánchez JM, Gutiérrez-Pizarraya A. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. Expert Rev Anti Infect Ther. 2015;13(6):769–777.
18. Basri R, Zueter AR, Mohamed Z, et al. Burden of bacterial meningitis: a retrospective review on laboratory parameters and factors associated with death in meningitis, Kelantan Malaysia. Nagoya J Med Sci. 2015;77(1–2):59.
19. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582.
20. Jung J, Park W. Acinetobacter species as model microorganisms in environmental microbiology: current state and perspectives. Appl Microbiol Biotechnol. 2015;99(6):2533–2548.
21. Islahi S, Ahmad F, Khare V, Yaqoob S, Shukla P, Singh Y. Incidence and risk factors associated with Acinetobacter species infection in hospitalised patients in a tertiary care hospital in North-India. J Comm Dis. 2015;46(3):10–12.
22. Tibor P, Tudományegyetem P. Molecular epidemiological studies on sporadic and epidemic isolates of Acinetobacter baumannii [doctoral thesis]. Hungary: University of Pécs; 2013.
23. Schweppe Devin K, Harding C, Chavez Juan D, et al. Host-microbe protein interactions during bacterial infection. Chem Biol. 2015;22(11):1521–1530.
24. Kim SW, Oh MH, Jun SH, et al. Outer membrane protein A plays a role in pathogenesis of acinetobacter nosocomialis. Virulence. 2016;7(14):413–426.
25. Lee JS, Choi CH, Kim JW, Lee JC. Acinetobacter baumannii outer membrane protein A induces dendritic cell death through mitochondrial targeting. J Microbiol. 2010;48(3):387–392.
26. Nho JS, Jun SH, Oh MH, et al. Acinetobacter nosocomialis secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. Microb Pathog. 2015;81:39–45.
27. Barrie A, Gorman M. Acinetobacter baumannii—The New MRSA? Eplasty. 2016;16.
28. Rossi E, Longo F, Barbagallo M, et al. Glucose availability enhances lipopolysaccharide production and immunogenicity in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol. 2016;11(3):335–349.
29. Bose S, Ghosh AK. Understanding of quorum–sensing: a possible solution for drug resistance in bacteria. Int J Curr Microbiol App Sci. 2016;5(2):540–546.
30. Abraham W-R. Going beyond the control of quorum-sensing to combat biofilm infections. Antibiotics (Basel). 2016;5(1):3.
31. Antunes LC, Imperi F, Towner KJ, Visca P. Genome-assisted identification of putative iron-utilization genes in Acinetobacter baumannii and their distribution among a genotypically diverse collection of clinical isolates. Res Microbiol. 2011;162(3):279–284.
32. Ferreira D, Seca AM, Diana C, Silva AM. Targeting human pathogenic bacteria by siderophores: a proteomics review. J Proteomics. 2016;145: 153–166.
33. Zarrilli R. Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells. Virulence. 2016:1–2.
34. Fleming A. Penicillin Nobel Lecture. December 11, 1945.
35. Khan MF, Aziz F. Antibiotic resistance: preparation for post-antibiotic era. EC Microbiology. 2016;3:409–411.
36. Landecker H. Antibiotic resistance and the biology of history. Body Soc. 2016;22(4):19–52.
37. Bathoorn E, Tsioutis C, da Silva Voorham J, et al. Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call. J Antimicrob Chemother. 2016:71(5): 1207–1212.
38. Provasi Cardoso J, Cayô R, Girardello R, Gales AC. Diversity of mechanisms conferring resistance to β-lactams among OXA-23–pro-ducing Acinetobacter baumannii clones. Diagn Microbiol Infect Dis. 2016;85(1):90–97.
39. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291–304.
40. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan–drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009;30(03):257–263.
41. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;47(4):317–323.
42. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–762.
43. Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11(1): 21–26.
44. Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2016;60(5): 3127–3131.
45. Thi Khanh Nhu N, Riordan DW, Do Hoang Nhu T, et al. The induction and identification of novel Colistin resistance mutations in Acinetobacter baumannii and their implications. Sci Rep. 2016;6:28291.
46. Koksal I, Kaya S, Gencalioglu E, Yilmaz G. Evaluation of risk factors for intravenous colistin use-related nephrotoxicity. Oman Med J. 2016;31(4):318–321.
47. Trifi A, Abdellatif S, Daly F, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy. 2016;61(4): 190–196.
48. Ozkan G, Ulusoy S, Orem A, et al. How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother. 2013;57(8):3463–3469.
49. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Lakhal SB. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):1.
50. Ziaka M, Makris D, Markantonis S, Zakynthinos E. Safety of prolonged intraventricular administration of olistin methanesulphonate. J Neuroinfect Dis. 2016;7:207.
51. Myint T, Evans ME, Burgess DR, Greenberg RN. Respiratory muscle paralysis associated with colistin, polymyxin B, and muscle relaxants drugs: a case report. J Investig Med High Impact Case Rep. 2016;4(1):2324709616638362.
52. Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(8):3738–3745.
53. Silva A, Sousa AM, Alves D, Lourenço A, Pereira MO. Heteroresistance to colistin in Klebsiella pneumoniae is triggered by small colony variants sub-populations within biofilms. Pathog Dis. 2016;74(5):ftw036.
54. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;59(3):473–477.
55. Simsek F, Gedik H, Yildirmak M, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol. 2012;30(4):448.
56. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii. A multicentre, randomised, clinical trial. Clin Infect Dis. 2013;57(3):349–358.
57. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67(7):1607–1615.
58. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39.
59. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008;61(2):417–420.
60. Hong DJ, Kim JO, Lee H, et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2016;86(2):184–189.
61. Poulikakos P, Tansarli G, Falagas M. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis. 2014;33(10):1675–1685.
62. Yang Y-S, Lee Y, Tseng K-C, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(7): 4045–4054.
63. Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS One. 2016;11(6):e0157757.
64. Nepka M, Perivolioti E, Kraniotaki E, Politi L, Tsakris A, Pournaras S. In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii Clinical Isolates. Antimicrob Agents Chemother. 2016;60(11):6903–6906.
65. Hejnar P, Kolár M, Hájek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med. 1999;142:73–77.
66. Oikonomou O, Sarrou S, Papagiannitsis CC, et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis. 2015;15(1):1–6.
67. Gupta M, Lakhina K, Kamath A, et al. Colistin-resistant Acinetobacter baumannii ventilator-associated pneumonia in a tertiary care hospital: an evolving threat. J Hosp Infect. 2016;94(1):72–73.
68. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331–336.
69. Cunha BA, McDermott B, Nausheen S. Single Daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother. 2007;19(6):753–754.
70. Zhang Y-Y, Zhou L, Zhu D-M, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis. 50(4):267–281.
71. Stefani S, Dowzicky JM. Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Pharmaceuticals. 2016;9(4):74.
72. Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In vitro activity of tigecycline against Acinetobacter baumannii: global epidemiology and resistance mechanisms. In: Donelli G, editor. Advances in Microbiology, Infectious Diseases and Public Health. Volume 1. Cham: Springer International Publishing; 2016:1–14.
73. Grandesso S, Sapino B, Amici G, Mazzucato S, Solinas M, Gion M. Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii. New Microbiol. 2014;37(4):503–508.
74. Castro AL, Gutierrez GB, Ovalle V, Cortés J, Alvarez C. Comparing in vitro activity of tigecycline by using the disc diffusion test, the manual microdilution method, and the VITEK 2 automated system. Rev Argent Microbiol. 2010;42:208–211.
75. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52(3):181–186.
76. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;59(4):772–774.
77. Martínez-Guitián M, Vázquez-Ucha JC, Odingo J, et al. Synergy between Colistin and the signal peptidase (SPase) inhibitor MD3 is dependent on the mechanism of colistin resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2016: AAC. 00510-00516.
78. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
79. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–1263.
80. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–3484.
81. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril! Curr Opin Microbiol. 2005;8(5):518–524.
82. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of bla-OXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. JAntimicrob Chemother. 2010;65(10):2253–2254.
83. Morán-Barrio J, Cameranesi MM, Relling V, Limansky AS, Brambilla L, Viale AM. The Acinetobacter outer membrane contains multiple specific channels for carbapenem β-lactams as revealed by kinetic characterization analyses of imipenem permeation into Acinetobacter baylyi cells. Antimicrob Agents Chemother. 2017;61(3).
84. Buckner MM, Blair JM, La Ragione RM, et al. Beyond antimicrobial resistance: evidence for a distinct role of the AcrD efflux pump in salmonella biology. mBio. 2016;7(6):e01916.
85. Yoon E-J, Balloy V, Fiette L, Chignard M, Courvalin P, Grillot-Courva-lin C. Contribution of the Ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of Acinetobacter baumannii. mBio. 2016;7(3):e00697-16.
86. Lytvynenko I, Brill S, Oswald C, Pos KM. Molecular basis of poly-specificity of the small multidrug resistance efflux pump AbeS from Acinetobacter baumannii. J Mol Biol. 2016;428(3):644–657.
87. Li L, Hassan KA, Brown MH, Paulsen IT. Rapid multiplexed phenotypic screening identifies drug resistance functions for three novel efflux pumps in Acinetobacter baumannii. J Antimicrob Chemother. 2016;71(5):1223–1232.
88. Shrestha S, Tada T, Shrestha B, et al. Emergence of aminoglycoside resistance due to armA methylase in multi-drug resistant Acinetobacter baumannii isolates in a University Hospital in Nepal. J Nepal Health Res Counc. 2016;14(33):72.
89. Ugolotti E, Di Marco E, Bandettini R, Tripodi G, Biassoni R. The whole genome sequencing of Acinetobacter-calcoaceticus-baumannii complex strains involved in suspected outbreak in an Intensive Care Unit of a pediatric hospital. J Hosp Adm. 2016;5(6):81.
90. Charrier C, Salisbury A-M, Savage VJ, et al. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases. J Antimicrob Chemother. 2016;71(10):2831–2839.
91. Yang H, Hu L, Liu Y, Ye Y, Li J. Detection of the plasmid-mediated quinolone resistance determinants in clinical isolates of Acinetobacter baumannii in China. J Chemother. 2016/09/02 2016;28(5):443–445.
92. Ling B-D, Zhang L, Li X-Z. Antimicrobial resistance and drug efflux pumps in acinetobacter. In: Efflux-Mediated Antimicrobial Resistance in Bacteria. Li XZ, Elkins CA, Zgurskaya HI, editors. Springer International Publishing: Springer; 2016:329–358.
93. Bojkovic J, Richie DL, Six DA, et al. Characterization of an Acinetobacter baumannii lptD deletion strain: permeability defects and response to inhibition of lipopolysaccharide and fatty acid biosynthe-sis. J Bacteriol. 2016;198(4):731–741.
94. Choi HJ, Kil MC, Choi J-Y, et al. Characterisation of successive Acinetobacter baumannii isolates from a deceased haemophagocytic lym-phohistiocytosis patient. Int J Antimicrob Agents. 2017;49(1):102–106.
95. Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
96. McGann P, Snesrud E, Maybank R, et al. Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: first report of mcr-1 in the USA. Antimicrob Agents Chemother. 2016;60(7):4420–4421.
97. Ahmed SS, Alp E, Hopman J, Voss A. Global epidemiology on colistin resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2016;35(9):1469–1468.
98. Schmelcher M, Loessner MJ. Bacteriophage endolysins: applications for food safety. Curr Opin Biotechnol. 2016;37:76–87.
99. Lin N-T, Chiou P-Y, Chang K-C, Chen L-K, Lai M-J. Isolation and characterization of φAB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol. 2010;161(4):308–314.
100. García-Quintanilla M, Pulido MR, López-Rojas R, Pachón J, McConnell MJ. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol. 2013;21(3):157–163.
101. Mohamed MF, Brezden A, Mohammad H, Chmielewski J, Seleem MN. A short D-enantiomeric antimicrobial peptide with potent immunomodula-tory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Sci Rep. 2017;7:6953.
102. Luo G, Spellberg B, Gebremariam T, et al. Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia. Eur J Clin Microbiol Infect Dis. 2014;33(5):845–851.
103. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239–251.
104. Bashir T, Ahmed A. Colistin Resistance among Gram Negative Organisms; an Evolving Problem from Tertiary Care Hospital, Pakistan 2014. American Journal of Microbiology. 2016.
105. Qadeer A, Akhtar A, Ain QU, et al. Antibiogram of Medical Intensive Care Unit at Tertiary Care Hospital Setting of Pakistan. Cureus. 2016;8(9):809.
106. Gupta M, Lakhina K, Kamath A, et al. Colistin-resistant Acinetobacter baumannii ventilator-associated pneumonia in a tertiary care hospital: an evolving threat. Journal of Hospital Infection. 2016;94(1):72–73.
107. Pawar SK, Karande GS, Shinde RV, Pawar VS. Emergence of Colistin Resistant Gram Negative Bacilli, in a Tertiary Care Rural Hospital from Western India. Indian Journal of Microbiology Research. 2016;3(3):308–313.
108. Am, Kaur e, Gill AK, et al. Prevalence and Antibiogram of Acinetobacter spp. Isolated from Various Clinical Samples in a Tertiary Care Hospital, Bathinda. IJHSR. 2016;6(6):83–89.
109. Samawi A, Saad M, Khan FY, et al. Acinetobacter Infections among Adult Patients in Qatar: A 2-Year Hospital-Based Study. Canadian Journal of Infectious Diseases and Medical Microbiology. 2016;2016.
110. Maraki S, Mantadakis E, Mavromanolaki VE, Kofteridis DP, Samonis G. A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital. Infect Chemother. 2016;48(3):190–198.
111. Al-Samaree MY, Al-Khafaji ZM. Antibiogram of Acinetobacter baumannii isolated from Baghdad Hospitals. Int. J. Adv. Res. Biol. Sci. 2016;3(4):238–242.
112. Alaei N, Aziemzadeh M, Bahador A. Antimicrobial resistance profiles and genetic elements involved in carbapenem resistance in Acinetobacter baumannii isolates from a referral hospital in Southern Iran. Journal of Global Antimicrobial Resistance. 2016;5:75–79.
113. El-Shazly S, Dashti A, Vali L, Bolaris M, Ibrahim AS. Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii. International Journal of Infectious Diseases. 2015;41:42–49.
114. Maspi H, Hosseini HM, Amin M, Fooladi AAI. High prevalence of extensively drug-resistant and metallo beta-lactamase-producing clinical Acinetobacter baumannii in Iran. Microbial Pathogenesis. 2016;98:155–159.
115. Ambrosi C, Aleandri M, Giordano A, et al. Molecular characterisation of extensively drug-resistant Acinetobacter baumannii: First report of a new sequence type in Italy. Journal of Global Antimicrobial Resistance. 2016;7:154–156.
116. Chang K-C, Lin M-F, Lin N-T, et al. Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. Journal of Microbiology, Immunology and Infection. 2012;45(1):37–42.
117. Rossi F, Girardello R, Cury AP, Gioia TSRD, Almeida Jr. JNd, Duarte AJdS. Emergence of colistin resistance in the largest university hospital complex of São Paulo, Brazil, over five years. The Brazilian Journal of Infectious Diseases. 2017;21(1):98–101.
118. Batarseh A, Al-Sarhan A, Maayteh M, Al-Khatirei S, Alarmouti M. Antibiogram of multidrug resistant Acinetobacter baumannii isolated from clinical specimens at King Hussein Medical Centre, Jordan: a retrospective analysis. Eastern Mediterranean Health Journal. 2016;21(11):828.
119. Qureshi ZA, Hittle LE, O’Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clinical infectious diseases. 2015;60(9):1295–1303.
120. Tojo M, Mawatari M, Hayakawa K, et al. Multidrug-resistant Aci-netobactor baumannii isolated from a traveler returned from Brunei. Journal of Infection and Chemotherapy. 2015;21(3):212–214.
121. Baadani AM, Thawadi SI, El-Khizzi NA, Omrani AS. Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period. Saudi medical journal. 2013;34(3):248–253.
122. Cikman A, Gulhan B, Aydin M, et al. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia. International journal of medical sciences. 2015;12(9):695.
123. Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options. Clinical infectious diseases. December 1, 2014 2014;59(suppl 6): S367–S373.
124. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of Tigecycline and Colistin Resistance in Acinetobacter Species Isolated from Patients in Kuwait Hospitals. Journal of Chemotherapy. 2011/02/01 2011;23(1):13–16.
125. Ghasemian R, Ahanjan M, Fatehi E, Shokri M. Prevalence and Antibiotic Resistance Pattern of Acinetobacter Isolated from Patients Admitted in ICUs in Mazandaran, Northern Iran. Global journal of health science. 2016;8(11):112.
126. Kulah C, Celebi G, Aktas E, Mengeloglu Z, Comert F, Ankarali H. Unexpected Tigecycline Resistance Among Acinetobacter baumannii Isolates: High Minor Error Rate by Etest. Journal of Chemotherapy. 2009/08/01 2009;21(4):390–395.
127. Liao C-H, Kung H-C, Hsu G-J, et al. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. International journal of antimicrobial agents. 32:S192–S196.
128. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. International journal of antimicrobial agents. 32(1):29–32.
129. Behera B, Das A, Mathur P, Kapil A, Gadepalli R, Dhawan B. Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res. 2009;129(4):446–450.
130. Kim C-K, Lee Y, Lee H, et al. Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter. Diagn Microbiol Infect Dis. 2010;68(4):432–438.
131. Van TD, Dinh Q-D, Vu PD, et al. Antibiotic susceptibility and molecular epidemiology of Acinetobacter calcoaceticus-baumannii complex strains isolated from a referral hospital in northern Vietnam. Journal of Global Antimicrobial Resistance. 2014;2(4):318–321.
132. Garza-González E, Llaca-Díaz JM, Bosques-Padilla FJ, González GM. Prevalence of Multidrug-Resistant Bacteria at a Tertiary-Care Teaching Hospital in Mexico: Special Focus on Acinetobacter baumannii. Chemotherapy. 2010;56(4):275–279.
133. García C, Juliet L, Fernández V, et al. Multicenter study on the monitoring of in vitro susceptibility to tigeeyeline in Santiago, Chile]. Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia. 2009;26(3):220–226.
134. Rizek C, Ferraz JR, van der Heijden IM, et al. Activity of potential old and new drugs against multidrug-resistant gram-negatives. Journal of Infection and Chemotherapy. 21(2):114–117.
135. Ahmed NH, Baba K, Clay C, Lekalakala R, Hoosen AA. In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa. BMC Research Notes. 2012;5(1):215.
136. Capone A, D’Arezzo S, Visca P, Petrosillo N. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy. 2008;62(2):422–423.
137. Mendes RE, Farrell DJ, Sader HS, Jones RN. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005–2009). Diagnostic Microbiology and Infectious Disease. 2010;68(3):307–311.
138. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. International journal of antimicrobial agents. 2008;32(1):29–32.
139. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). Journal of Infection. 2010;60(6):440–451.
140. Bahador A, Taheri M, Pourakbari B, et al. Emergence of Rifampicin, Tigecycline, and Colistin-Resistant Acinetobacter baumannii in Iran; Spreading of MDR Strains of Novel International Clone Variants. Microbial Drug Resistance. 2013;19(5):397–406.
141. Hasan B, Perveen K, Olsen B, Zahra R. Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in Pakistan. Journal of Medical Microbiology. 2014;63(1):50–55.
142. Al-Agamy MH, Jeannot K, El-Mahdy TS, et al. First Detection of GES-5 Carbapenemase-Producing Acinetobacter baumannii Isolate. Microbial Drug Resistance. 2017;23(5):556–562.
143. Chmielarczyk A, Pilarczyk-Żurek M, Kamińska W, et al. Molecular Epidemiology and Drug Resistance of Acinetobacter baumannii Isolated from Hospitals in Southern Poland: ICU as a Risk Factor for XDR Strains. Microbial Drug Resistance. 2016;22(4):328–335.
144. Tsioutis C, Kritsotakis EI, Karageorgos SA, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. International journal of antimicrobial agents. 2016;48(5):492–497.